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Teddy Wu , MD; Muhib Khan, MD; Salah Keyrouz, MD; Karen Furie , MD; Nils Henninger , MD, PhD
BACKGROUND: Intravenous alteplase improves outcome after acute ischemic stroke without a benefit in 90-day mortality. There
are limited data on whether alteplase is associated with reduced mortality in patients with atrial fibrillation (AF)-related ischemic
stroke whose mortality rate is relatively high. We sought to determine the association of alteplase with hemorrhagic transformation and mortality in patients with AF.
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METHODS AND RESULTS: We retrospectively analyzed consecutive patients with acute ischemic stroke between 2015 and 2018
diagnosed with AF included in the IAC (Initiation of Anticoagulation After Cardioembolic Stroke) study, which pooled data from
stroke registries at 8 comprehensive stroke centers across the United States. For our primary analysis, we included patients
who did not undergo mechanical thrombectomy (MT), and secondary analyses included patients who underwent MT. We
used binary logistic regression to determine whether alteplase use was associated with risk of hemorrhagic transformation
and 90-day mortality. There were 1889 patients (90.6%) who had 90-day follow-up data available for analyses and were included; 1367 patients (72.4%) did not receive MT, and 522 patients (27.6%) received MT. In our primary analyses we found that
alteplase use was independently associated with an increased risk for hemorrhagic transformation (odds ratio [OR], 2.23; 95%
CI, 1.57–3.17) but reduced risk of 90-day mortality (OR, 0.58; 95% CI, 0.39–0.87). Among patients undergoing MT, alteplase
use was not associated with a significant reduction in 90-day mortality (OR, 0.68; 95% CI, 0.45–1.04).
CONCLUSIONS: Alteplase reduced 90-day mortality of patients with acute ischemic stroke with AF not undergoing MT. Further
study is required to assess the efficacy of alteplase in patients with AF undergoing MT.
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I

ntravenous alteplase improves outcomes in eligible
patients with acute ischemic stroke, albeit with up
to 6% risk of symptomatic intracranial hemorrhage

in early trials1 and lower rates with studies using real-
world data.2 Faster alteplase treatment is associated
with better functional outcomes.3 Clinical trials show
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CLINICAL PERSPECTIVE
What Is New?

• Intravenous alteplase is associated with reduced mortality in patients with atrial fibrillation
not receiving mechanical thrombectomy.

What Are the Clinical Implications?

• Prospective studies are needed to confirm our
findings and to determine whether alteplase indications can be safely expanded to patients with
atrial fibrillation on oral anticoagulant therapy.
• Future studies are also needed to establish
whether intravenous thrombolysis before mechanical thrombectomy is beneficial in cardioembolic stroke.

Nonstandard Abbreviations and Acronyms
ASPECTS
DIRECT-MT

Downloaded from http://ahajournals.org by on September 9, 2021

DOAC
IAC
MT
NIHSS
SKIP

Alberta Stroke Program Early CT
Score
Endovascular Thrombectomy With
or Without Intravenous Alteplase
in Acute Stroke
direct oral anticoagulant
Initiation of Anticoagulation in
Cardioembolic Stroke
mechanical thrombectomy
National Institutes of Health
Stroke Scale
Randomized Study of EVT With
Versus Without Intravenous
Recombinant Tissue-Type
Plasminogen Activator in Acute
Stroke With ICA and M1
Occlusion

no benefit in 90-day mortality in patients treated with
alteplase,4–6 likely because of limited efficacy in patients with increased stroke severity.5
Patients with atrial fibrillation (AF) are at high risk for
ischemic stroke, and stroke caused by AF is associated with increased risk of hemorrhagic transformation, functional disability, and mortality.2,7–10 There are
limited data on whether alteplase treatment improves
mortality in patients with AF.
We sought to determine the association of alteplase
treatment with the rate of hemorrhagic transformation
and 90-day mortality in patients with AF-associated
stroke.

METHODS
Institutional review board approval for the study was
obtained from each of the study sites. Data from this
study may be shared upon reasonable request to the
corresponding author.

Study Sample
This is a multicenter retrospective study that analyzed data from the IAC (Initiation of Anticoagulation in
Cardioembolic Stroke) study that included consecutive
patients with nonvalvular AF hospitalized for acute ischemic stroke and treated at 8 comprehensive stroke
centers in the United States for various periods across
sites but between the years 2015 and 2018. The aim
of the IAC study was to determine the optimal timing of
initiation of anticoagulation in patients with acute cardioembolic stroke. Details of the study methodology
have previously been described.11–13 For this analysis,
we included all patients in the IAC study except those
who were lost to follow-up within 90 days. The index
date was considered as the date stroke symptoms occurred or last known normal time.

Independent Variable (Predictor)
The primary predictor in this study was treatment with
intravenous alteplase.

Dependent Variables (Outcomes)
The coprimary study outcomes were 90-day mortality and early hemorrhagic transformation defined as
any hemorrhagic transformation on a brain imaging
(computed tomography or magnetic resonance imaging) in the first 24 to 48 hours and before initiation
of anticoagulation.13 Secondary outcomes were number of passes in mechanical thrombectomy (MT) and
successful reperfusion as determined by the treating
interventionalist defined as modified thrombolysis in
cerebral infarction score ≥2B.14

Covariates
The following covariates were collected as part of the
IAC study and selected a priori based on biological evidence to provide information about cardiovascular risk
as well as potential clinical and imaging factors associated with ischemic or hemorrhagic complications.
Baseline Demographics and Clinical Variables
Baseline demographics and clinical variables included
age, sex, history of hypertension, history of diabetes
mellitus, history of hyperlipidemia, history of prior stroke
or transient ischemic attack, active smoking, history
of congestive heart failure, history of coronary artery
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disease, admission National Institutes of Health Stroke
Scale (NIHSS) score (abstracted from the medical record and performed by a certified provider), CHA2DS2-
VASc score, and timing of initiating anticoagulation.
Home Medications
Home medications included aspirin and anticoagulation therapy (warfarin or direct anticoagulants).
Laboratory and Imaging Variables
Laboratory and imaging variables included serum glucose level on admission, infarct location (strictly posterior circulation involvement versus not), and largest
ischemic infarct size calculated on magnetic resonance imaging largest ischemic stroke lesion volume
determined on brain magnetic resonance imaging or
computed tomography if magnetic resonance imaging
was not obtained using the a×b×c/2 method.15

to determine associations between alteplase use and
the study outcomes adjusted for age and admission
NIHSS score. No imputations were made for missing
data. We used SPSS version 25.0 (IBM, Armonk, NY)
to perform the analysis, and a 2-sided P<0.05 was
considered statistically significant.

RESULTS
Out of 2084 patients included in the IAC study, 195
were lost to follow-up at 90 days (Table S1), leaving
1889 patients for the analysis. The mean age was
77.2±11.8 years, 51.8% were women, 32.0% had a history of stroke or transient ischemic attack, 35.6% were
on anticoagulation before the ischemic stroke, 522 patients received MT, and 1367 patients did not receive
MT. Figure 1 shows the flowchart of the study.
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Statistical Analysis

Patients Without Thrombectomy
Treatment

Given the known overwhelming benefit of MT as well
as inherently different stroke characteristics between
patients eligible versus not eligible for MT, we stratified
our analyses based on whether patients received MT
or not. For univariate comparisons we used χ2 or Fisher
exact test for categorical variables, as indicated, and t
test or nonparametric (Mood’s median test) tests for
continuous variables, as indicated. We created unadjusted and adjusted binary logistic regression models

Among patients not treated with MT, those who received intravenous alteplase were less likely to have
hypertension (78.7% versus 84.2%, P=0.03), diabetes
mellitus (28.7% versus 37.4%, P=0.005), a prior stroke
or transient ischemic attack (27.0% versus 36.2%,
P=0.003), strictly posterior circulation infarcts (13.6%
versus 21.4% P<0.001), or be on anticoagulation at

Figure 1.

Univariate Analyses in Patients Without
Thrombectomy Treatment

Study flowchart.
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home (19.0% versus 41.9%, P<0.001). Conversely,
patients treated with alteplase were more likely to be
on aspirin at home (54.0% versus 45.5%, P=0.011)
and have a higher initial median (interquartile range)
NIHSS score (8 [4–15] versus 6 [2–14], P=0.002). Other
baseline characteristics were not significantly different
between the 2 groups (Table 1). The percentages of
NIHSS score categories (≤5, 6–10, 11–15, >15) are displayed in Figure 2.
Patients receiving intravenous alteplase were more
likely to have hemorrhagic transformation (20.3% versus 10.2%, P<0.001) but did have a lower 90-day mortality rate (14.3% versus 19.8%, P=0.029) (Table 1).

intravenous alteplase use was associated with increased
odds of hemorrhagic transformation (adjusted OR, 2.14;
95% CI, 1.49–3.07; P<0.001) but a reduced 90-day mortality (adjusted OR, 0.58; 95% CI, 0.39–0.87; P=0.009).
The association between alteplase treatment and reduced mortality persisted when certain mortality predictors such as diabetes mellitus and prior stroke were
included in the model (adjusted OR, 0.58; 95% CI 0.38–
0.87; P=0.009). Furthermore, the association between
alteplase treatment and increased odds of hemorrhagic
transformation persisted when admission glucose level
and anticoagulation use were included in the model (adjusted OR, 2.21; 95% CI, 1.49–3.07; P<0.001).

Association Between Alteplase
Treatment and Outcomes

Patients With Thrombectomy Treatment

In unadjusted analyses, intravenous alteplase use was
associated with increased odds of hemorrhagic transformation (odds ratio [OR], 2.24; 95% CI, 1.59–
3.16;
P<0.001) but a reduced 90-
day mortality (OR, 0.68;
95% CI, 0.47–0.96; P=0.030). These findings persisted
in adjusted binary logistic regression showing that

Among patients treated with MT, patients who received
intravenous alteplase were older (78.6±11.8 versus
76.4±12.4 years, P=0.043), less likely to be on oral anticoagulation at home (15.7% versus 47.4%, P<0.001),
and had higher low-density lipoprotein LDL level reported as median (interquartile range) (77 [59–
99]

Univariate Analyses

Table 1. Factors Among Patients Not Undergoing Mechanical Thrombectomy With Versus Without Alteplase
Nonalteplase, n=1067
Age, y, mean±SD

Alteplase, n=300

P value
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77.0±11.5

77.6±12.0

0.468

Sex, % men

49.0% (523/1067)

52.7% (158/300)

0.267

Hypertension, %

84.2% (898/1067)

78.7% (236/300)

0.030

Diabetes mellitus, %

37.4% (399/1066)

28.7% (86/300)

0.005

Hyperlipidemia, %

58.0% (618/1066)

53.7% (161/300)

0.187

Prior stroke or TIA, %

36.2% (386/1067)

27.0% (81/300)

0.003
0.256

Active smoking, %

13.4% (126/938)

10.7% (28/262)

Congestive heart failure, %

27.0% (286/1046)

25.8% (77/298)

0.657

Coronary artery disease, %

33.8% (358/1059)

31.7% (95/300)

0.532

7.7% (80/1038)

4.8% (14/294)

0.093
0.104

Peripheral vascular disease, %

5 (4–6)

5 (3–6)

Aspirin, %

CHA 2DS2-VASc, median (IQR)

45.5% (482/1059)

54.0% (162/300)

0.011

Anticoagulation at home, %

41.9% (444/1059)

19.0% (57/300)

<0.001

NIHSS score, median (IQR)

6 (2–14)

8 (4–15)

0.002

Systolic blood pressure, mean±SD
Glucose, mg/dL, mean±SD

152.8±29.1

150.2±28.4

0.164

123 (103–153)

124 (103–149)

0.684

LDL, mg/dL, mean±SD

77 (59–104)

83 (60–110)

0.084

Posterior circulation, %

21.4% (208/971)

13.4% (37/277)

<0.001

3 (1–7)

4 (2–10)

<0.001

38.2% (361/944)

40.8% (106/260)

0.473

Hemorrhagic transformation, %

10.2% (109/1067)

20.3% (61/300)

<0.001

Death within 90 d, %

20.0% (212/1067)

14.3% (43/300)

0.029

Interval to start anticoagulation,
median (IQR)
Final infarct size ≤10 mL, %
Outcomes

Interval to start anticoagulation is the interval from index event to initiation of anticoagulation. Anticoagulation is any therapeutic anticoagulation (eg, direct oral
anticoagulant, warfarin, heparin, lovenox). Largest ischemic infarct size was calculated on MRI as the largest ischemic stroke lesion volume determined on brain
MRI or computed tomography that shows the infarct if MRI was not obtained using the a×b×c/2 method. IQR indicates interquartile range; LDL, low-density
lipoprotein; MRI, magnetic resonance imaging; NIHSS, National Institutes of Health Stroke Scale; and TIA, transient ischemic attack.
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Figure 2. The percentage of patients (y axis) with the National Institutes of Health Stroke Scale
(NIHSS) score categories (x axis) in patients with or without alteplase stratified by whether they
received thrombectomy (lower part) or did not receive thrombectomy (upper part).
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versus 70 [52–93], P=0.023). Other baseline characteristics were not significantly different between the 2
groups (Table 2). The percentages of NIHSS score categories (≤5, 6–10, 11–15, >15) are displayed in Figure 2.
Patients receiving intravenous alteplase tended to
require fewer thrombectomy passes, though this was
not statistically significant (median, 1; interquartile range,
1–2 versus median, 2; interquartile range, 1–2; P=0.074).
There was no significant difference in the rate of successful recanalization (modified thrombolysis in cerebral
infarction ≥2B, 91.8% versus 92.3%, P=0.729), hemorrhagic transformation (29.7% versus 33.7%, P=0.346),
and 90-day mortality (28.9% versus 31.4%, P=0.566)
between patients treated with alteplase versus patients
not treated with alteplase (Table 2).

90-day mortality (OR, 0.89; 95% CI, 0.61–1.30; P=0.537)
or hemorrhagic transformation (OR, 0.83; 95% CI, 0.57–
1.20; P=0.324). In adjusted binary logistic regression
models, intravenous alteplase treatment was associated
with a nonsignificantly lower 90-day mortality (adjusted
OR, 0.68; 95% CI, 0.45–1.04; P=0.077), but the odds of
hemorrhagic transformation (adjusted OR, 0.82; 95% CI,
0.56–1.20; P=0.312) did not differ between the 2 groups.
Results of the association between alteplase use and
mortality remained unchanged when prior stroke and diabetes mellitus were included in the model (adjusted OR,
0.74; 95% CI, 0.48–1.13; P=0.164). Furthermore, results of
the association between alteplase use and hemorrhagic
transformation remained unchanged when admission
glucose level and anticoagulation use were included in the
model (adjusted OR, 0.72; 95% CI, 0.48–1.08; P=0.108).

Association Between Alteplase
Treatment and Outcomes

Additional Analyses

In unadjusted analyses, intravenous alteplase treatment
was not associated with a difference in the odds of

Because warfarin treatment with international normalized ratio >1.7 and direct oral anticoagulant (DOAC)

Table 2. Factors Among Patients Undergoing Mechanical Thrombectomy With Versus Without Alteplase
Nonalteplase (n=290)
Age, y, mean±SD

Alteplase (n=232)

P value
0.043

Downloaded from http://ahajournals.org by on September 9, 2021

76.4±12.4

78.6±11.8

Sex, % women

43.4% (126/290)

44.8% (104/232)

0.790

Hypertension, %

81.9% (236/288)

80.2% (186/232)

0.652

27.9% (80/287)

23.8% (55/231)

0.315
0.064

Diabetes mellitus, %
Hyperlipidemia, %

54.2% (156/288)

45.7% (106/232)

Prior stroke or TIA, %

28.8% (83/288)

23.3% (54/232)

0.162

Active smoking, %

12.4% (31/250)

14.0% (29/207)

0.677

Congestive heart failure, %

23.9% (68/285)

24.9% (57/229)

0.836

Coronary artery disease, %

0.101

32.9% (95/289)

26.0% (60/231)

Peripheral vascular disease, %

7.3% (20/275)

4.2% (9/216)

0.178

CHA 2DS2-VASc, median (IQR)

4 (3–6)

4 (3–6)

0.977

Aspirin, %

37.3% (107/287)

44.4% (103/230)

0.088

Anticoagulation at home, %

<0.001

47.4% (136/287)

15.7% (36/230)

NIHSS, median, IQR

17 (11–22)

18 (13–23)

0.140

Systolic blood pressure, mean±SD

145.7±27.9

145.9±26.4

0.920

125 (106–150)

119 (102–144)

0.156
0.023

Glucose, median (IQR)
LDL, median (IQR)

70 (52–93)

77 (59–99)

8.6% (22/257)

4.3% (9/207)

0.091

Interval to start anticoagulation,
median (IQR)

7 (2–14)

7 (3.5–14)

0.202

Largest infarct size ≤20 mL, %

50.6% (125/247)

55.4% (112/202)

0.342

Posterior circulation, %

Outcomes
No. of passes, median (IQR)

2 (1–2)

1 (1–2)

0.074

Successful recanalization, %

92.8% (244/263)

91.8% (191/208)

0.729

Hemorrhagic transformation, %

33.8% (98/290)

29.7% (69/232)

0.346

Death within 90 d, %

31.4% (91/290)

28.9% (67/232)

0.566

Interval to start anticoagulation is the interval from index event to initiation of anticoagulation. Anticoagulation is any therapeutic anticoagulation (eg, direct oral
anticoagulant, warfarin, heparin, lovenox), and largest ischemic infarct size was calculated on MRI largest ischemic stroke lesion volume determined on brain
MRI or computed tomography that shows the infarct if MRI was not obtained using the a×b×c/2 method. IQR indicates interquartile range; LDL, low-density
lipoprotein; MRI, magnetic resonance imaging; NIHSS, National Institutes of Health Stroke Scale; and TIA, transient ischemic attack.
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treatment within 48 hours before the index stroke represent contraindications for alteplase, we conducted
additional analyses comparing mortality and hemorrhagic transformation rates in patients with AF on oral
anticoagulant therapy with warfarin (n=349) or DOAC
(n=327) who received alteplase versus those who did
not.
As expected, patients on warfarin at home who
did not receive alteplase had a significantly higher
mean international normalized ratio level (1.7±0.8 versus 1.4±0.3, P<0.001). In models adjusted for age and
NIHSS score, the mortality rate at 90 days was lower
in those receiving intravenous alteplase as compared
with those who did not receive alteplase (adjusted OR,
0.29; 95% CI, 0.13–0.67; P=0.004). Nevertheless, patients who received intravenous alteplase were more
likely to have hemorrhagic transformation as compared
with patients who were not treated with alteplase (adjusted OR, 3.37; 95% CI, 1.77–6.43; P<0.001).
In patients on DOAC treatment, adjusted models
(adjusting for age and NIHSS score) showed that the
mortality rate at 90 days (adjusted OR, 0.51; 95% CI,
0.12–2.13; P=0.357) and hemorrhagic transformation
(adjusted OR, 0.23; 95% CI, 0.03–1.79; P=0.159) were
not significantly different between groups.
Furthermore, to account for patient clustering by
study site, we fit mixed-
effects logistic regression
models to our outcomes. The mixed-effects model estimates a separate intercept for each study site to account for between-hospital differences, such as case
volume or proportion of cases treated with alteplase or
MT as well as MT patient selection. In these analyses,
our findings on associations between alteplase treatment and 90-day mortality were essentially the same
in patients not treated with thrombectomy (adjusted
OR, 0.58; 95% CI, 0.38–0.87; P=0.009) and in patients
treated with thrombectomy (adjusted OR, 0.68; 95%
CI, 0.45–1.04; P=0.077).
Moreover, we performed interaction analyses to determine whether the effect of alteplase on study outcomes was different in patients with versus without MT
treatment. In these analyses, the effect of alteplase on
mortality was not significantly different in patients with
versus without MT treatment (P-interaction=0.616).
On the other hand, the effect of alteplase on the
odds of hemorrhagic transformation was more pronounced in patients with versus without MT treatment
(P-interaction<0.001).
Finally, we performed matched analyses using propensity score matching (caliper set at 0.05, matched
1:1) for hemorrhagic transformation (matched for age,
NIHSS score, glucose, and anticoagulation use) and
mortality (matched for age, NIHSS score, history of
diabetes mellitus, and prior stroke). In these analyses, alteplase treatment was associated with reduced
mortality (OR, 0.48; 95% CI, 0.32–0.73) but increased

Alteplase and Mortality in Stroke

hemorrhagic transformation (OR, 1.71; 95% CI, 1.10–
2.65) in patients not receiving MT (n=596 patients). On
the other hand, alteplase was not associated with either mortality (OR, 1.08; 95% CI, 0.69–1.71) or hemorrhagic transformation (OR, 0.74; 95% CI, 0.48–1.15) in
patients receiving MT (n=366 patients).

DISCUSSION
We found that intravenous alteplase treatment was associated with a reduced 90-day mortality in patients
with acute ischemic stroke in the setting of AF who
were not treated with MT. Among patients undergoing MT, there was a nonsignificantly lower number of
passes and mortality in subjects that were treated with
intravenous alteplase as compared with those who did
not receive intravenous alteplase.
The decrease in mortality we observed in patients with AF who did not receive MT is consistent
with prior studies encompassing all mechanisms of
stroke.16 However, these findings are slightly different
than other studies that showed no significant mortality benefit of intravenous alteplase in patients with
acute ischemic stroke and AF.17 It should be noted,
however, that these studies were done before MT
became a standard of care for patients presenting
with acute large-vessel occlusion stroke. Intravenous
alteplase treatment (versus none) without MT has
limited benefit in patients with proximal large-vessel
occlusion,18 which may explain the negative findings
in some of the aforementioned studies. Conversely,
stroke systems of care have considerably improved
over time, leading to faster and safer administration
of intravenous alteplase,2,19 which may account for
some of the observed improved efficacy of intravenous alteplase treatment in our study compared with
the previous studies.20,21
We found a nonsignificantly lower mortality with
alteplase in patients with AF who received MT. This
is consistent with the pivotal thrombectomy trials,
which did not demonstrate an effect on mortality or
outcome.22,23 This is also in line with recent studies
showing no significant added benefit of alteplase use
in patients with proximal occlusion undergoing MT24,25
and possibly related to the limited efficacy of alteplase
in achieving successful reperfusion in patients with
proximal large-artery occlusion. Nonetheless, our findings highlight the need to further study this issue, particularly because stroke patients with AF have worse
clinical outcomes after MT compared patients without
AF.26

Mechanisms of Associations
There are several potential mechanisms by which intravenous alteplase treatment improved mortality in
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patients with AF who were not selected for thrombectomy in our study. Arguably, the main mechanism related to thrombolysis of clots within smaller27 and more
distal28,29 vessels, which tend to respond favorably to
alteplase. Unsurprisingly, there was increased risk of
hemorrhagic transformation associated with intravenous alteplase use, which is likely multifactorial and related to induced coagulopathy, reperfusion injury, and
disruption of the blood–brain barrier.2,30 Presumably,
most of these hemorrhages were asymptomatic given
the overall lower mortality rate associated with alteplase use in our study. Conversely, another explanation to our findings is that patients with extensive early
signs of ischemia on initial brain imaging were not considered eligible for intravenous alteplase or thrombectomy, thus explaining the increased mortality in the
nonalteplase group.
Prior large meta-
analyses have shown that benefit of intravenous alteplase in patients undergoing
thrombectomy extends to not only mortality but also
improvement in functional outcome as well as increased procedural success rates without increase
in symptomatic hemorrhage.31,32 Most recently, the
SKIP (Randomized Study of EVT With Versus Without
Intravenous Recombinant Tissue-
Type Plasminogen
Activator in Acute Stroke With ICA and M1 Occlusion)
study33 demonstrated a lack of noninferiority of foregoing intravenous alteplase treatment in favor of direct MT. Furthermore, the DIRECT-MT (Endovascular
Thrombectomy With or Without Intravenous Alteplase
in Acute Stroke) trial showed that endovascular therapy alone was noninferior to endovascular therapy
plus alteplase in achieving improved functional independence at 90 days.23 In this trial, however, patients
treated with alteplase were more likely to achieve successful reperfusion.

Therapeutic Implications
The benefit of intravenous alteplase in acute stroke
within 4.5 hours of onset is now well established, but
up to 25% of eligible patients fail to receive alteplase
treatment partially as a consequence of provider
bias.34 Our analysis suggests that patients with AF
with acute ischemic stroke should receive intravenous
alteplase when eligible, despite the slightly higher risk
of a hemorrhagic conversion within this subgroup. In
addition, a large number of acute ischemic stroke patients have a contraindication to alteplase, of which
being anticoagulated is not uncommon.35 In our
analysis, premorbid anticoagulation for AF was more
common in patients who did not receive intravenous
alteplase, as would be expected. However, recent evidence suggests that the use of warfarin for stroke prevention in AF has become less frequent than the use
of DOACs.36 Although DOACs have a favorable safety
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profile, one disadvantage is that rapid laboratory tests
are not available to measure their therapeutic effect. As
a result, patients with AF taking DOACs are not eligible
to receive intravenous alteplase, unless they missed
taking their medication within 24 to 48 hours of the
index stroke. Although prethrombolysis DOAC reversal has been reported,37,38 rapid reversal of warfarin or
DOACs for intravenous alteplase treatment is presently
not recommended because of the risk of additional
thrombosis created by their rapid reversal.39 Because
our analysis showed a mortality benefit for intravenous
alteplase in patients with AF, it is appealing to further
study the risk versus benefit of intravenous alteplase
therapy in patients with AF on DOAC treatment.40 A
recent meta-analysis indicated that intravenous thrombolysis in select patients treated with DOAC did not
to increase the risk of symptomatic intracerebral hemorrhage.41 Furthermore, in patients with AF with high
risk of stroke, such as extensive atherosclerosis of the
cerebrovasculature or CHA2DS2-VASc >5, one consideration would be left atrial appendage occlusion
with subsequent antiplatelet therapy, which recent
data suggest provides comparable efficacy compared
with anticoagulation in stroke risk reduction.42,43 This
will obviate the need for long-term anticoagulation and
may potentially make these patients alteplase eligible if
they were to have to an ischemic stroke.

Strengths and Limitations
Our study has several limitations including the retrospective and observational nature that may have introduced bias. Although we adjusted for potential
confounders, we cannot rule out residual confounding. In addition, our findings may have been affected
by contraindications to intravenous alteplase, which
may have favored treatment of less-sick patients and
those without large or already completed infarcts at
presentation. However, this appears less likely, because in our study, patients treated with alteplase
were older and had a higher initial NIHSS. Another
limitation relates to the lack of data on several factors that have been associated with outcome after MT
such as the time from symptom onset to treatment,
perfusion imaging findings, ASPECTS (Alberta Stroke
Program Early CT Score), collateral status, and location of where large-vessel occlusion is. Moreover, we
used the a×b×c/2 method to calculate infarct volume,
which has been validated but is not commonly used
in patients with ischemic stroke. Furthermore, the lack
of information on time to treatment in patients who received alteplase or MT, as well as possible heterogeneity in patient selection for thrombectomy across the
study period, are additional limitations. These limitations, however, are unlikely to affect our findings, because the time to alteplase is only available for those
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treated with alteplase and does not apply to untreated
patients, and thrombectomy treatment was being
used in all participating centers during the study duration. In addition, follow-up imaging was performed at
the discretion of the provider and thus may have contributed to bias. Finally, the relatively high proportion of
patients without a recorded 90-day modified Rankin
Scale score precluded a more detailed analysis of the
effect on functional disability.
Notable strengths of our study include its multicenter design and inclusion of a large cohort of patients that provided real-world contemporary data in
the era of MT treatment. In addition, using validated
methodology, we captured data on infarct volume,
which was not included in prior studies, particularly
in those studying the efficacy of alteplase in patients
without thrombectomy.

CONCLUSIONS
Intravenous alteplase use was associated with reduced
mortality in patients with acute ischemic stroke not undergoing MT. Larger prospective studies are needed to
confirm our findings and to determine whether alteplase
indication can be safely expanded to patients with AF
on oral anticoagulant therapy, and future studies are
needed to establish whether intravenous thrombolysis
before MT is beneficial in cardioembolic stroke.
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Table S1. Baseline characteristics of patients who were lost to follow up.
Age (years, mean ± SD)
Sex (% men)
Hypertension (%)
Diabetes (%)
Hyperlipidemia (%)
Prior stroke or TIA (%)
Active smoking (%)
Congestive heart failure (%)
Coronary artery disease (%)
Peripheral vascular disease (%)
CHA2DS2-Vasc, median (IQR)
NIHSS score, median (IQR)
Alteplase treatment
Mechanical thrombectomy

Lost to follow up (n = 195)
77.3 ± 11.6
43.6% (85)
76.9% (150)
26.2% (51)
62.6% (122)
32.3% (63)
12.2% (23/188)
25.6% (50)
24.6% (48)
5.8% (11/189)
5 (3-6)
6 (2-15)
29.7% (58)
12.8% (25)
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